Although direct-to-consumer advertising (DTCA) has generated substantial controversy, little is known about its effects on consumer and physician behavior. In this article, the authors examine the impact of DTCA and physician detailing on the choice of antidepressant medication. The authors find that detailing has a much greater effect on medication choice in the antidepressant market than does DTCA.
Get full access to this article
View all access options for this article.
References
1.
AndersonI.M., and TomensonB.M. (1994), “The Efficacy of Selective Serotonin Reuptake Inhibitors in Depression: A Meta-Analysis of Studies Against Tricyclic Antidepressants,”Journal of Psychopharmcology, 8, 238–49.
2.
AndersonI.M., and TomensonB.M. (1995), “Treatment Discontinuation with Selective Serotonin Reuptake Inhibitors Compared with Tri-Cyclic Antidepressants: A Meta-Analysis,”British Medical Journal, 310 (6992), 1433–38.
3.
BerndtErnst R., BhattacharjyaA., MisholD.N., ArcelusA., and LaskyT. (2002), “An Analysis of the Diffusion of New Anti-depressants: Variety, Quality, and Marketing Efforts,”Journal of Mental Health Policy and Economics, 5, 3–19.
4.
BerndtErnst R., BuiLinda T., ReileyDavid H., and UrbanGlen L. (1997), “The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Antiulcer Drug Industry,” in The Economics of New Products, Studies in Income and Wealth, Vol. 58, BresnahanTimothy F., and GordonRobert J., eds. Chicago: University of Chicago Press for the National Bureau of Economic Research, 277–322.
5.
BondRonald S., and LeanDavid F. (1997), Sales, Promotion and Product Differentiation in Two Prescription Drug Markets.Washington, DC: Staff Report of the Bureau of Economics of the Federal Trade Commission.
6.
BroadheadW.E. (1994), “Misdiagnosis of Depression: Physicians Contribute to the Stigmatization of Mental Illness,”Archives of Family Medicine, 3, 319.
7.
DelgadoP.L., and GelenbergA.J. (2001), “Antidepressant and Antimanic Medications,” in Treatments for Psychiatric Disorders, GabbardG.O., ed. Washington, DC: American Psychiatric Press, 1131–68.
8.
Depression Guideline Panel (1993a), Depression in Primary Care Volume I: Detection and Diagnosis.Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (accessed July 18, 2003), [available at http://www.mentalhealth.com/bookah/p44-d2.html].
9.
Depression Guideline Panel (1993b), Depression in Primary Care Volume II: Treatment of Major Depression.Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (accessed July 18, 2003), [available at http://www.mentalhealth.com/bookah/p44-d2.html].
10.
DonohueJ.M., BerndtE.R., EpsteinA.M., RosenthalM.B., and FrankR.G. (2004), “Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression,”Medical Care, (December), forthcoming.
11.
FDA (1999a), “Attitudes and Behaviors Associated with Direct-to-Consumer Promotion of Prescription Drugs,”Office of Medical Policy, Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research, (accessed August 4, 2004), [available at http://www.fda.gov/cder/ddmac/dtctitle.htm].
12.
FDA (1999b), “Guidance for Industry: Broadcast Advertising of Prescription Drugs,”Department of Health and Human Services (accessed October 2003), [available at http://www.fda.gov/cder/guidance/1804fnl.htm].
13.
FDA (2000), Department of Health and Human Services, Prescription Drug Advertising Regulations, 21 CFR 202.1.
FrankR.G. (2001), “Prescription Drug Prices: Why Do Some Pay More than Others?”Health Affairs, 20 (2), 115–28.
17.
FrankR.G., BerndtE.R., DonohueJ., EpsteinA.M., and RosenthalM. (2001), Trends in Direct-to-Consumer Advertising of Prescription Drugs.Menlo Park, CA: Henry J. Kaiser Family Foundation (accessed July 2003), [available at http://www.kff.org].
18.
GonulF., CarterF., PetrovaE., and SrinivasanK. (2001), “Promotion of Prescription Drugs and Its Impact on Physician's Choice Behavior,”Journal of Marketing, 65 (3), 79–90.
19.
HausmanJ., and McFaddenD. (1984), “Specification Tests for the Multinomial Logit Model,”Econometrica, 52 (5), 1219–40.
20.
HollonM.F. (1999), “Direct-to-Consumer Marketing of Prescription Drugs,”Journal of the American Medical Association, 281 (4), 382–84.
21.
HolmerA.F. (2002), “Direct-to-Consumer Advertising— Strengthening our Health Care System,”New England Journal of Medicine, 346 (7), 526–28.
22.
HurwitzMark A., and CavesRichard E. (1988), “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals,”Journal of Law and Economics, 31 (October), 299–320.
23.
HuskampH.A. (2003), “Managing Psychotropic Drug Costs: Will Formularies Work?”Health Affairs, 22 (5), 84–96.
24.
HuskampH.A., DeverkaP.A., EpsteinA.M., EpsteinR.S., McGuiganK.A., and FrankR.G. (2003), “The Impact of Incentive-Based Formularies on Prescription Drug Utilization and Spending,”New England Journal of Medicine, 349 (23), 2224–32.
25.
IizukaT., and JinG.Z. (2003), “The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets,” working paper, Vanderbilt University.
KesslerR.C., BerglundP., DemlerO., JinR. (2003), “The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R),”Journal of the American Medical Association, 289 (23), 3095–3105.
30.
KingCharlesIII (2000), “Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs,” Working Paper No. 01-014, Harvard Business School, Boston.
31.
KroenkeK., WestS.L., SwindleR., GilsenanA. (2001), “Similar Effectiveness of Paroxetine, Fluoxetine and Sertraline in Primary Care,”Journal of the American Medical Association, 286 (23), 2947–55.
32.
LefflerKeith B. (1981), “Promotion or Information? The Economics of Prescription Drug Advertising,”Journal of Law and Economics, 24 (April), 45–74.
33.
LiebowitzA., ManningW.G., and NewhouseJ.P. (1985), “The Demand for Prescription Drugs as a Function of Cost-Sharing,”Social Science and Medicine, 21, 251–77.
34.
LingD.C., BerndtE.R., and KyleM.K. (2003), “Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales,”Journal of Law and Economics, 45, 691–723.
35.
McFaddenD. (1981), “Econometric Models of Probabilistic Choice,” in Structural Analysis of Discrete Data, ManskiC., and McFaddenD., eds. Cambridge, MA: MIT Press, 198–272.
36.
McGuireT.G. (2001), “Physician Agency,” in Handbook of Health Economics, Vol. 1a, CulyerA.J., and NewhouseJ.P., eds. Amsterdam/New York: Elsevier, 17.
37.
Medical Economics Company (2002), Physicians’ Desk Reference, 56th ed. Montvale, NJ: Medical Economics Company, Inc.
NewhouseJ.P. (1993), Free for All.Cambridge, MA: Harvard University Press.
40.
OlfsonM., MarcusS., DrussB., ElinsonL. (2002), “National Trends in the Outpatient Treatment of Depression,”Journal of the American Medical Association, 287 (2), 203–209.
41.
OrmelJ., VonKorffM., UstunT.B., PiniS., KortenA., and OldehinkelT. (1994), “Common Mental Disorders and Disability Across Cultures: Results from the WHO Collaborative Study on Psychological Problems in General Health Care,”Journal of the American Medical Association, 272 (22), 1741–48.
42.
ReederC., and NelsonA. (1985), “The Differential Impact of Copayment on Drug Use in a Medicaid Population,”Inquiry, 22, 396–403.
43.
RizzoJohn A. (1999), “Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs,”Journal of Law and Economics, 42 (1), 89–116.
44.
RosenthalM.B., BerndtE.R., DonohueJ.M., EpsteinA.M., and FrankR.G. (2003), “Demand Effects of Recent Changes in Prescription Drug Promotion,” in Frontiers in Health Policy Research, Vol. 6, CutlerD.M., and GarberA.M., eds. Cambridge, MA: MIT Press, 1–26.
45.
RosenthalM.B., BerndtE.R., DonohueJ.M., FrankR.G., and EpsteinA.M. (2002), “Promotion of Prescription Drugs to Consumers,”New England Journal of Medicine, 346 (7), 498–505.
46.
RostK., SmithG.R., MatthewsD.B., and GuseB. (1994), “The Deliberate Misdiagnosis of Major Depression in Primary Care,”Archives of Family Medicine, 3, 333–37.
47.
SlaughterEd, and SchumacherMartha (2001), “International Survey on Wellness and Consumer Reaction to DTC Advertising of Prescription Drugs,”Prevention Magazine, I, 46–55.
48.
SoumeraiS.B., McLaughlinT.J., and AvornJ. (1989), “Improving Drug Prescribing in Primary Care: A Critical Analysis of the Experimental Literature,”Milbank Quarterly, 67 (2), 268–317.
49.
SpinaE., and ScordoM.G. (2002), “Clinically Significant Drug Interactions with Antidepressants in the Elderly,”Drugs Aging, 19 (4), 299–320.
50.
SpitzerR.L., KroenkeK., LinzerM., HahnS.R. (1995), “Health-Related Quality of Life in Primary Care Patients with Mental Disorders: Results from the PRIME-MD 1000 Study,”Journal of the American Medical Association, 274 (19), 1511–17.
51.
VernonJohn (1981), “Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry,”Journal of Industrial Economics, 19 (3), 246–66.
52.
WeissmanJ.S., BlumenthalD., SilkA.J., ZapertK., NewmanM., and LeitmanR. (2003), “Consumers’ Reports on the Health Effects of Direct-to-Consumer Drug Advertising,”Health Affairs, (February), [available at http://www.healthaffairs.org].
53.
WolfeS.M. (2002), “Direct-to-Consumer Advertising—Education or Emotion Promotion?”New England Journal of Medicine, 346 (7), 524–26.
54.
WosinskaM. (2002), “Promoting to Multiple Agents: The Case of Direct-to-Consumer Drug Advertising,” doctoral dissertation, Department of Economics, University of California, Berkeley.
55.
ZachryW.M., ShepherdM.D., HinichM.J., WilsonJ.P., BrownC.M., and LawsonK.A. (2002), “Relationship Between Direct-to-Consumer Advertising and Physician Diagnosing and Prescribing,”American Journal of Health-System Pharmacy, 59 (1), 42–49.
